


## CRT0066101 dihydrochloride

<b>Cat. No.:</b>	HY-15698A
<b>CAS No.:</b>	1883545-60-5
<b>Molecular Formula:</b>	C <sub>18</sub> H <sub>24</sub> Cl <sub>2</sub> N <sub>6</sub> O
<b>Molecular Weight:</b>	411.33
<b>Target:</b>	PKD; Apoptosis; Pim
<b>Pathway:</b>	Apoptosis; JAK/STAT Signaling
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : 50 mg/mL (121.56 mM; Need ultrasonic)  
DMSO : 11.36 mg/mL (27.62 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	2.4311 mL	12.1557 mL	24.3114 mL
	5 mM	0.4862 mL	2.4311 mL	4.8623 mL
	10 mM	0.2431 mL	1.2156 mL	2.4311 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: PBS  
Solubility: 25 mg/mL (60.78 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 1.14 mg/mL (2.77 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 1.14 mg/mL (2.77 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 1.14 mg/mL (2.77 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

CRT0066101 dihydrochloride is a potent and orally active PKD inhibitor with IC<sub>50</sub> values of 1 nM, 2.5 nM and 2 nM for PKD1, PKD2, and PKD3, respectively<sup>[1]</sup>. CRT0066101 dihydrochloride is also a potent PIM2 inhibitor with an IC<sub>50</sub> of ~135.7 nM. CRT0066101 dihydrochloride has anticancer effects<sup>[2]</sup>.

#### IC<sub>50</sub> & Target

PKD1	PKD3	PKD2	PIM2
1 nM (IC <sub>50</sub> )	2 nM (IC <sub>50</sub> )	2.5 nM (IC <sub>50</sub> )	135.7 nM (IC <sub>50</sub> )

<b>In Vitro</b>	<p>CRT0066101 (5 <math>\mu</math>M; 1 h) dihydrochloride blocks both the basal and NT-induced pS916-PKD1/2 (activated PKD1/2) in Panc-1 and Panc-28 cells. CRT0066101 dihydrochloride abrogates NT-induced phosphorylation of Hsp27 (pS82-Hsp27), attenuates PKD1-mediated NF-<math>\kappa</math>B activation, and abrogates expression of NF-<math>\kappa</math>B-dependent-dependent proliferative and pro-survival proteins<sup>[1]</sup>.</p> <p>CRT0066101 dihydrochloride significantly inhibits Panc-1 cell proliferation, with an IC<sub>50</sub> value of 1 <math>\mu</math>M. CRT0066101 dihydrochloride results in a 6-10 fold induction of apoptosis in Panc-1 cells. CRT0066101 dihydrochloride significantly reduces cell proliferation of Colo357, Panc-1, MiaPaCa-2, and AsPC-1 cells but had a modest effect in Capan-2 cells<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis<sup>[1]</sup></p>								
	<table border="1"> <tr> <td>Cell Line:</td> <td>Panc-1 and Panc-28 cells stimulation with neurotensin (NT)</td> </tr> <tr> <td>Concentration:</td> <td>5 <math>\mu</math>M</td> </tr> <tr> <td>Incubation Time:</td> <td>1 h</td> </tr> <tr> <td>Result:</td> <td>Blocked both the basal and NT-induced pS916-PKD1/2 (activated PKD1/2).</td> </tr> </table>	Cell Line:	Panc-1 and Panc-28 cells stimulation with neurotensin (NT)	Concentration:	5 $\mu$ M	Incubation Time:	1 h	Result:	Blocked both the basal and NT-induced pS916-PKD1/2 (activated PKD1/2).
	Cell Line:	Panc-1 and Panc-28 cells stimulation with neurotensin (NT)							
	Concentration:	5 $\mu$ M							
	Incubation Time:	1 h							
Result:	Blocked both the basal and NT-induced pS916-PKD1/2 (activated PKD1/2).								
<b>In Vivo</b>	<p>CRT0066101 (80 mg/kg/day; oral gavage; once daily; for 21 days) dihydrochloride in Panc-1 orthotopic model potentially blocks tumor growth in vivo<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								
	<table border="1"> <tr> <td>Animal Model:</td> <td>CR-UK nu/nu mice injected with Panc-1 cells<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>80 mg/kg/day</td> </tr> <tr> <td>Administration:</td> <td>Oral gavage; once daily; for 21 days</td> </tr> <tr> <td>Result:</td> <td>Potentially blocked tumor growth in vivo.</td> </tr> </table>	Animal Model:	CR-UK nu/nu mice injected with Panc-1 cells <sup>[1]</sup>	Dosage:	80 mg/kg/day	Administration:	Oral gavage; once daily; for 21 days	Result:	Potentially blocked tumor growth in vivo.
	Animal Model:	CR-UK nu/nu mice injected with Panc-1 cells <sup>[1]</sup>							
	Dosage:	80 mg/kg/day							
	Administration:	Oral gavage; once daily; for 21 days							
Result:	Potentially blocked tumor growth in vivo.								

## CUSTOMER VALIDATION

- Exp Mol Med. 2022 Sep 21.
- Int Immunopharmacol. 2023 May 12;120:110240.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Xi Chen, et al. Identification and assessment of new PIM2 inhibitors for treating hematologic cancers: A combined approach of energy-based virtual screening and machine learning evaluation. Arch Pharm (Weinheim). 2024 Jan 23:e2300516.

[2]. Harikumar KB, et al. A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo. Mol Cancer Ther. 2010 May;9(5):1136-46.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA